Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.

@article{Shitara2017PhaseID,
  title={Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.},
  author={Kohei Shitara and Tae Min Kim and Tomoya Yokota and Masahiro Goto and Taroh H Satoh and Jin-hee Ahn and Hyo Song Kim and Sylvie Assadourian and Corinne Gomez and Marzia Harnois and Satoshi Hamauchi and Toshihiro Kudo and Toshihido Doi and Yung-Jue Bang},
  journal={Oncotarget},
  year={2017},
  volume={8 45},
  pages={
          79546-79555
        }
}
SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and MET amplification (NCT01657214). SAR125844 was administered by intravenous infusion (260-570 mg/m2) on days 1, 8, 15, and 22 of each 28-day cycle. Objectives were to determine the maximum tolerated dose (MTD) and to evaluate SAR125844 safety… CONTINUE READING
BETA